December 11, 2008
Genta to Appeal FDA Decision on New Drug Application for Genasense® in Patients with Chronic Lymphocytic Leukemia
December 4, 2008
Tesetaxel, a Leading Oral Taxane in Clinical Development, Receives FDA Designation as an Orphan Drug for Treatment of Patients with Advanced Melanoma
December 2, 2008
Genta Receives Complete Response Letter from FDA to Amended Application of Genasense® in Patients with Chronic Lymphocytic Leukemia
November 6, 2008
Genta Incorporated Announces Third Quarter 2008 Financial Results and Corporate Highlights
November 3, 2008
Genta Incorporated to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
October 30, 2008
Genta Incorporated to Host Conference Call to Discuss Third Quarter Highlights and Financial Results
October 6, 2008
Genta Updates Progress of its Phase 3 Trial of Genasense® in Patients with Advanced Melanoma(2)
October 2, 2008
Genta Announces Webcast of 2008 Annual Shareholders Meeting
September 15, 2008
Independent Monitoring Board Recommends Completion of Accrual to Genasense® Phase 3 AGENDA Trial in Advanced Melanoma
August 7, 2008
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
July 31, 2008
Genta Announces Second Quarter 2008 Financial Results and Conference Call
July 14, 2008
FDA Accepts Genta® NDA Amendment as Complete Response for Genasense® Treatment of Chronic Lymphocytic Leukemia
June 24, 2008
Genta Updates Progress of its Phase 3 Trial of Genasense® in Patients with Advanced Melanoma
June 23, 2008
FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane
June 10, 2008
Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
June 9, 2008
Genta Announces First Closing of its $40 Million Convertible Financing Facility; Issues $20 Million in Senior Secured Convertible Notes
June 6, 2008
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
June 5, 2008
Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
June 2, 2008
Genta Announces Initial Clinical Trial Results for G4544, a Novel Potent Drug for Bone Disease
May 30, 2008
Genasense® Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
May 29, 2008
Long-Term Followup in Phase 3 CLL Trial Shows Genasense® is Associated with Significantly Increased Survival in All Responders
May 21, 2008
Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
May 8, 2008
Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
May 6, 2008
Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
May 6, 2008
Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
April 30, 2008
Genta Announces First Quarter 2008 Financial Results
April 14, 2008
Genta Receives Key Patent Related to Oral Gallium Compound G4544
April 7, 2008
Specialized Genasense Clinical Trials Featured at AACR Meeting
April 2, 2008
Genta Restructures Operations to Focus on Priority Initiatives
March 31, 2008
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense® in Advanced Melanoma
March 27, 2008
Genta Granted Extenison To Achieve Compliance With Nasdaq Listing Requirements
March 20, 2008
Auditors for Genta Incorporated Express Going Concern Qualification
March 17, 2008
FDA Indicates that Genasense® Approval in Chronic Lymphocytic Leukemia will Require Additional Confirmatory Data
March 12, 2008
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
March 7, 2008
Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel
March 5, 2008
Genta Announces Fourth Quarter and Year End 2007 Conference Call
February 22, 2008
Genta Announces Senior Management Changes
February 11, 2008
Genta Announces Common Stock Offering of Approximately $3.1 Million
February 5, 2008
Genta Incorporated to Present at the BIO CEO & Investor Conference
January 14, 2008
FDA Extends Review Of GENASENSE® NDA Appeal in Chronic Lymphocytic Leukemia
January 11, 2008
Genta Receives Notice of Non-Compliance with Nasdaq Rule
